The debate over prostate cancer screening with PSA testing is far from over, as evidenced by the response to the recent USPTF recommendation. Medscape Medical News
No Comments »
Filed under: General Health News
Patients with advanced prostate cancer in Scotland will not get access to a new drug which can extend their lives by more than three months. Prostate cancer is the most common cancer to affect men and the second most common cause of death.
No Comments »
Filed under: Pharmacy News
Circumcised men might have a lower risk of developing prostate cancer, according to a new analysis. Medscape Medical News
No Comments »
Filed under: General Health News
Cancer Research UK is extremely disappointed that the advanced prostate cancer drug, abiraterone, has been ruled too expensive for routine use by the Scottish Medicines Consortium (SMC).
No Comments »
Filed under: Pharmacy News
(MedPage Today) — Older men with low-risk prostate cancer received increasingly aggressive treatment over a 10-year period, whereas practices did not change for men most likely to benefit from curative therapy, a study showed.
No Comments »
Filed under: General Health News
Active Biotech’s and Ipsen’s castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.
No Comments »
Filed under: Pharmacy News
Cancer Research UK welcomes the news that the All Wales Medicines Strategy Group (AWMSG) has made prostate cancer drug abiraterone available on the NHS, paving the way for NICE to make a positive ruling when they publish their final guidance in May.
No Comments »
Filed under: Pharmacy News
The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer [...]
No Comments »
Filed under: Pharmacy News
After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.
No Comments »
Filed under: Pharmacy News
An FDA panel of oncologists has voted against a new use for Amgen’s Xgeva in prostate cancer on Wednesday, saying the drug’s ability to slow the spread of the disease did not translate into meaningful benefits for patients. Xgeva is already approved to prevent fractures in cancerous bones, and for osteoporosis, in a different formulation [...]
No Comments »
Filed under: Pharmacy News
